Stayble Therapeutics closes investment round of 9 MSEK for upcoming clinical trials

Stayble develop a new treatment for chronic back pain with the goal to offer patients a simple efficient injection treatment that is effective within a few weeks. Stayble have now secured SEK 9 million in investment.

The investment will create conditions for taking Stayble to the next level and take the company through an initial clinical trial to verify that the treatment is safe and tolerable in humans. Among the investors are Almi Invest Västsverige AB, Chalmers Ventures and a number of smaller investors from Gothenburg as well as Skåne and Stockholm.

"The great interest from existing owners, combined with a handful of strong new investors means that the company is in a good situation for the future development of the company," says Andreas Gerward, CEO Stayble Therapeutics AB.

More information: stayble.se